Connect with us

Press Release

Cardio Diagnostics Inks Groundbreaking Telehealth Agreement With Navierre And Expands Access To Cardiovascular Tests

Published

on

–News Direct–

By Jeremy Golden, Benzinga

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention and early detection more precise, has inked a new deal with an innovative digital health technology platform.

Cardio Diagnostics strategic partnership with Navierre which revolutionizes how patients access healthcare by acting as a true health companion for every stage of life aims to significantly expand access to Cardio Diagnostics' industry-leading, AI-enabled precision cardiovascular diagnostic tests.

On April 1, Cardio Diagnostics precision heart health solutions, including its flagship AI-powered epigenetic-genetic cardiovascular risk, detection and management tests, became available to thousands of patients and clinicians on Navierres platform.

Now, Navierre-partnered clinicians across the United States can seamlessly order these tests for their patients. Consumers can easily register for a profile on the platform by filling out a health questionnaire and requesting a test.

Those clinical tests, Epi+Gen CHD and PrecisionCHD, only require a blood sample that can be collected in provider settings, at home or via mobile phlebotomy. This ease of collection will enable Cardio Diagnostics partnership with Navierre to leverage the growing telehealth market and revolutionize the patient cardiovascular care journey through earlier detection, accessible specialty care and personalized prevention.

We are thrilled to partner with Navierre to make our industry-leading cardiovascular clinical tests more widely available to patients and clinicians nationwide, said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. Navierres innovative platform aligns with our mission to transform cardiovascular care through AI-driven precision diagnostics and personalized prevention strategies.

Cardiovascular Market Growth

Nearly 50% of Americans live with diabetes, obesity, hypertension or another major cardiovascular risk, according to the Centers for Disease Control and Prevention (CDC). Cardiovascular disease is the leading cause of death worldwide, accounting for nearly 19 million deaths annually.

This impact on a growing number of people across the world means the demand for cardiovascular diagnostics has never been higher. Companies in the field are in a position to achieve robust growth as they strive to meet the demand.

Projections indicate a Compound Annual Growth Rate (CAGR) of 5.1% in the cardiovascular diagnostics market, whose market valuation is expected to reach $9.7 billion by 2033. This surge can be attributed to the escalating demand for sophisticated and accessible diagnostic technologies in the fight against cardiovascular diseases.

Following this upward trend, the digital health and telehealth markets are poised for growth that has been fueled by the rapid adoption of telehealth services and the integration of AI technologies.

The AI healthcare market, which is also poised for significant growth, had an estimated size of $22.45 billion in 2023, a number thats expected to accelerate at a CAGR of 36.4%. Finally, the telehealth market, with a valuation of $128.12 billion in 2022, is forecasted to quadruple by 2030 to $504.24 billion.

These developments have changed the healthcare landscape and underscore the Cardio Diagnostics-Navierre partnerships positioning to capitalize on these market shifts.

Navierre provides a digital health platform that can integrate Cardio Diagnostics tests into a broader telehealth ecosystem, expanding access and facilitating earlier cardiovascular risk detection. That means the flexibility of Cardio Diagnostics tests will pave the way for rapid nationwide scaling with minimal infrastructure barriers.

Thus, the partnership could make specialty cardiology care more readily available for all communities, including those that are often underserved. By expanding the sites of care to telehealth and remote-enabled provider organizations, this partnership addresses the critical issue of increasing wait times for specialty care while democratizing access to top-tier heart disease services.

This collaboration directly responds to current diagnostic methods' limitations, offering a scalable solution that extends to remote zip codes in the U.S.

Advances In The Fight Against The Top Cause Of Death

The COVID-19 pandemic has accelerated the adoption of digital health solutions, with the CDC reporting that 36% of adults used telehealth services in 2021. McKinsey & Company estimates that up to $250 billion of U.S. healthcare spending could be virtualized, representing about 20% of all Medicare, Medicaid and commercial outpatient, office and home health expenditures.

This shift to digital health and AI-driven diagnostics could have a broad impact on the cardiovascular detection, care and management industry.

Across the country, there is a need for more accessible and systemic healthcare solutions. This new partnership offers an important response to the goal of combating cardiovascular diseases globally while committing to health equity and access.

Cardio Diagnostics groundbreaking testing solutions are an exciting addition to our curated list of products and services we offer to our users, said Mustafa Dinani, CEO and co-founder of Navierre.

By combining our innovative platform with their AI-driven precision diagnostics, we empower patients and clinicians with the tools they need to identify cardiovascular risk early when it can be most effectively addressed. Together, we are making significant strides in the fight against the worlds leading cause of death, he said.

Featured photo by Ali Hajiluyi on Unsplash

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (Core Technology) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com.

Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases will, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," goal, or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Companys ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading Risk Factors in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Gene Mannheimer – Investor Relations

+1 855-226-9991

investors@cardiodiagnosticsinc.com

Company Website

https://cardiodiagnosticsinc.com/

View source version on newsdirect.com: https://newsdirect.com/news/cardio-diagnostics-inks-groundbreaking-telehealth-agreement-with-navierre-and-expands-access-to-cardiovascular-tests-127263786

Cardio Diagnostics Holdings, Inc

comtex tracking

COMTEX_450743714/2655/2024-04-12T08:46:38

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

New Action-Packed Thriller “Christmas in Havana” Explores Love and Loyalties Amidst International Intrigue

Published

on

Centreville, VA – Christmas in Havana, the gripping third installment of Stephen Hiemstra’s Masquerade series, is now available. Combining political intrigue, action, and romance, Hiemstra’s latest novel dives deep into the complexities of love and loyalty in the face of personal grief and international crisis.

Luke Stevens, a CIA agent working undercover as a pastor, finds himself haunted by his ex-wife’s death as he eulogizes her. Just when Luke is ready to move forward, North Korean law student Ruth Chǔ (Yong Dae Chû) enters his life. She is secretly entangled in a dangerous game of espionage, working as a courier for North Korea’s Reconnaissance General Bureau (RGB) to support her family. Both Luke and Ruth must navigate their complicated pasts and present loyalties, all while international tensions threaten to boil over.

When China’s plan to invade Taiwan comes to light, with Cuba playing a key role in the diversionary attacks, Luke and Ruth are thrown into a whirlwind of danger. The novel raises the stakes with rogue operatives, international betrayal, and a contract placed on Luke’s life. Despite the chaos surrounding them, Luke and Ruth form a bond, quietly supporting each other as they face impossible choices.

Hiemstra’s skillful writing combines fast-paced action with thoughtful character development. Readers are treated to rapid-fire dialogue and a suspenseful plot that turns on a dime, keeping them on the edge of their seats. As Luke and Ruth struggle with their own personal dilemmas, Hiemstra skillfully weaves in commentary on international politics, hinting at larger global consequences and political missteps.

Praise for Christmas in Havana

“Having traveled to Havana, I can attest to the city’s rich history and intrigue, and Stephen Hiemstra captures this perfectly. Christmas in Havana is a thrilling read filled with action and suspense.”

— Percy M. Burns, Author of Glorious Freedom

“Stephen Hiemstra guides readers through a captivating adventure that reflects life itself, blending action and emotion with ease. Christmas in Havana is a fascinating story of love, loyalty, and survival.”

— Julio Martinez, Senior Pastor, Shadai Phoenix Church

“Christmas in Havana is a powerful conclusion to Hiemstra’s trilogy. It’s a fast-moving drama full of romance, action, and spiritual reflection.”

— Sharron Giambanco, Business Owner and Writer

About the Author

Stephen W. Hiemstra (MDiv, PhD) is a husband, father, and writer with a passion for Christian spirituality and ministry. After a 27-year career as an economist with the U.S. government, Hiemstra transitioned into ministry, serving as a pastor and writer. He has published numerous books, including Called Along the Way and A Christian Guide to Spirituality, and writes regularly on his blog. Stephen holds a Master of Divinity from Gordon-Conwell Theological Seminary and a PhD in Agricultural Economics from Michigan State University.

For more information and to sign up for Stephen’s newsletter,

Visit www.stephenwhiemstra.net

Contact Information:

Contact Person : Stephen W. Hiemstra

Email: t2pneuma@gmail.com

Blog: https://t2pneuma.net

Books: https://t2pneuma.com

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

A Darkly Comic Journey into the Absurd with Slaphappy by Dug Brown

Published

on

Dug Brown’s latest novel, Slaphappy, is a hilariously eccentric and daringly unpredictable tale that dives deep into the absurdities of human nature, morality, and the chaotic pursuit of fame. Set in a morally decaying society, Slaphappy follows the life of Bruiser, the irreverent host of the Atlanta-based internet game show Greed, where contestants are enticed to sacrifice their moral values for cash rewards.

This bold novel blends dark humor with elements of New Age smut, bringing readers a unique genre mashup that explores the fringes of human desires and moral boundaries. The novel takes an unexpected turn when Bruiser encounters Bootleg, a mysterious transient, during a show taping. After receiving a handful of change from Bootleg, Bruiser wakes up three days later with an uncanny ability: he can heal people by slapping them. What follows is a bizarre and darkly humorous journey across the country, as Bruiser embarks on a slap-fueled healing tour, raising questions about his sanity and whether his newfound power is a curse or a blessing.

 As Bruiser slaps his way through moral dilemmas, addictions, and a deep-seated disdain for humanity, the novel explores complex themes, including the savior complex, societal decay, and the human obsession with finding heroes in the most unlikely places. His bizarre journey is further complicated by his growing relationship with Vanessa, his new producer, who sees the entertainment potential in his powers, yet senses a deeper purpose behind his strange gift.

Brown’s writing, reminiscent of satirists like Philip Roth and Ishmael Reed, takes readers on a thought-provoking, surreal, and often darkly comedic ride. Through Bruiser’s exploits, Slaphappy satirizes reality TV, the pursuit of the American Dream, and the fine line between good and evil. 

Praise for Slaphappy

Slaphappy challenges readers to reflect on their own beliefs, fears, and anxieties through a blend of ultra-black humor, vivid surrealism, and characters who exist on the fringes of society. Bruiser’s story, while outlandish, embodies the darkest fears and desires of the modern world, creating a narrative that is as entertaining as it is thought-provoking.

With its irreverent tone and unpredictable twists, Slaphappy is a must-read for fans of dark comedy, New Age smut, and unconventional storytelling. Dug Brown’s unique voice, honed by years of bartending and transcendent spiritual practices, brings a raw, authentic edge to the novel, blending satire with a profound commentary on human nature.

Slaphappy is now available for purchase and promises to take readers on a wild, unforgettable journey.

Contact Information:

Contact Person: Dug Brown

Website: www.dugbrown.com

Email: dugbrown3@gmail.com

Dug Brown has spent most of his life observing humanity from behind a bar, where much of his dialogue and perspective on human nature was shaped. A Reiki master and Johrei practitioner, Brown brings a transcendental perspective to his writing. Having studied film in Los Angeles, Brown worked as a screenwriter before venturing into documentary filmmaking and eventually returning to the South. Slaphappy is part of a broader library of thought-provoking novels that aim to take readers from the darkness of human experience into the light of a new generation.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Life Bank Chain Launches ERC-20 Token System to Drive Innovation in Genetic Research

Published

on

Life Bank Chain Introduces a New Paradigm in Genetic Data Management with Dr. Randy Schekman

Life Bank Chain, a player in blockchain-based healthcare solutions, has announced the launch of its ERC-20 token framework to bridge the gap between genetic research and blockchain. This revolutionary model aims to incentivize scientists and researchers to share data, driving innovation in personalized medicine and accelerating medical breakthroughs.

With Nobel Laureate Dr. Randy Schekman lending his expertise in biology, Life Bank Chain’s initiative promises to set a new standard in the fusion of blockchain and genetic research. This approach enhances efficiency, transparency, and collaboration, addressing critical challenges in healthcare while laying the foundation for a more open and secure research ecosystem.

“Blockchain offers a unique solution to manage research contributions and reward innovation,” said Dr. Randy Schekman, advisor to Life Bank Chain. “This project has the potential to unlock new frontiers in healthcare by making research more accessible and incentivizing breakthroughs.”

Building a Collaborative and Transparent Research Ecosystem

Life Bank Chain’s ERC-20 token framework incentivizes the collection and sharing of genetic data by rewarding contributors with digital tokens. These tokens aim to foster an environment of transparency, making research more efficient and accessible while encouraging collaborative efforts between scientists and healthcare professionals.

The project’s tokenized ecosystem also presents a compelling opportunity for investors, as it is designed to drive exponential growth through active participation and innovative contributions. Life Bank Chain’s dual focus on blockchain and biology positions it as a game-changer in both healthcare and decentralized finance.

Transforming Personalized Medicine with Blockchain Technology

The ERC-20 token system is just one aspect of Life Bank Chain’s mission to redefine personalized healthcare. Dr. Schekman’s extensive background in cellular biology informs the development of DNA and RNA-based solutions, with a focus on creating therapies tailored to individual genetic profiles.

This fusion of blockchain technology with personalized medicine ensures that data is secure, decentralized, and accessible only to those with authorized access. Life Bank Chain’s innovative model allows patients and researchers alike to maintain control over sensitive genetic data while fostering new breakthroughs in medical science.

“This initiative encourages both collaboration and security, empowering researchers to drive progress while respecting data privacy,” said Dr. Schekman.

About Life Bank Chain

Life Bank Chain is a pioneer in blockchain-based healthcare solutions, focusing on secure genetic data management and personalized medicine. With the involvement of Nobel Laureates Dr. Randy Schekman and Dr. Eric Maskin, the company combines cutting-edge biology with advanced blockchain technology to create innovative healthcare solutions. Life Bank Chain’s mission is to bridge the gap between science and decentralized finance, driving both data security and medical advancements.

Website: https://lifebankchain.io/

Media Contact

Contact person : Ryan Chris – CEO

Email: contactus@lifebankchain.io

Website: https://lifebankchain.io/

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST